A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients

A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients

We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spik...

Full description

Bibliographic Details
Main Authors: Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Hiroya Ichikawa, Hironori Sakai, Wataru Hojo, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, Shigeki Nagao, Akihito Kitao, Yoshiharu Miyata, Taiji Koyama, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Vaccines
Subjects:
SARS-CoV-2 vaccination
allogeneic hematopoietic stem cell transplantation
BNT162b2
mRNA-1273
COVID-19
vaccination
Online Access:https://www.mdpi.com/2076-393X/10/11/1830

Internet

https://www.mdpi.com/2076-393X/10/11/1830

Similar Items